J. Carroll
Président chez ESPERION THERAPEUTICS, INC.
Fortune : 2 M $ au 30/04/2024
Postes actifs de J. Carroll
Sociétés | Poste | Début | Fin |
---|---|---|---|
CATALENT, INC. | Directeur/Membre du Conseil | 29/08/2023 | - |
Independent Dir/Board Member | 28/07/2015 | - | |
Président | 01/07/2023 | 29/08/2023 | |
ESPERION THERAPEUTICS, INC. | Président | 01/06/2022 | - |
Independent Dir/Board Member | 01/06/2022 | - | |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Directeur/Membre du Conseil | 01/07/2015 | - |
Historique de carrière de J. Carroll
Anciens postes connus de J. Carroll
Sociétés | Poste | Début | Fin |
---|---|---|---|
MALLINCKRODT PLC | Directeur/Membre du Conseil | 28/06/2013 | 16/06/2022 |
Independent Dir/Board Member | 28/06/2013 | 16/06/2022 | |
THERAPEUTICSMD, INC. | Directeur/Membre du Conseil | 18/03/2015 | 31/12/2021 |
Independent Dir/Board Member | 18/03/2015 | 31/12/2021 | |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Directeur/Membre du Conseil | 01/03/2016 | 23/06/2016 |
Président | 23/06/2016 | 01/01/2018 | |
DURATA THERAPEUTICS INC | Directeur/Membre du Conseil | 26/08/2014 | 17/11/2014 |
VIVUS, INC. | Directeur/Membre du Conseil | 13/05/2013 | 01/09/2014 |
Independent Dir/Board Member | 10/05/2013 | 01/09/2014 | |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | 01/01/2012 | 01/01/2013 |
░░░░░░░░░░ ░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░ ░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░ ░░░░░░░░ ░ ░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de J. Carroll
Holy Cross College (Indiana) | Undergraduate Degree |
Babson College | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 16 |
Irlande | 2 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 11 |
Independent Dir/Board Member | 5 |
Chairman | 3 |
Sectorielle
Health Technology | 14 |
Consumer Services | 4 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
MERCK & CO., INC. | Health Technology |
MALLINCKRODT PLC | Health Technology |
THERAPEUTICSMD, INC. | Health Technology |
CATALENT, INC. | Health Technology |
ESPERION THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 9 |
---|---|
Accredo Health, Inc.
Accredo Health, Inc. Services to the Health IndustryHealth Services Accredo Health, Inc. provides specialty retail pharmacy services in the United States. The company is into the sale of drugs for the recurring treatment of chronic and potentially life threatening diseases. Their services includes specialty retail pharmacy services, clinical services, reimbursement services, delivery services and other support services customized for individual therapies. It was founded in 1980 and is headquartered in Memphis, TN. | Health Services |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
VIVUS, Inc.
VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Durata Therapeutics, Inc.
Durata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL. | Health Technology |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
- Bourse
- Insiders
- J. Carroll
- Expérience